This is an open label, single arm, prospective, multi-centric clinical trial to evaluate the efficacy and tolerability of Dysmegesic, 750 mg. Female subjects aged between 16 and 30 years (both inclusive) suffering from primary dysmenorrhea (PD) of moderate to severe severity and meeting all inclusion and no exclusion criteria will be enrolled in the study after signing a written informed consent/assent form. Diagnosis  was based on the subject’s history and physical examination.During the screening/enrollment, demographic details such as date of birth, education and occupation details will be obtained. Medical history, details of prior and concomitant medications will be elicited. The study procedures will be explained and instructions regarding study assessments will be provided.After passing the eligibility criteria, the subjects will be dispensed the test formulation (Dysmegesic, 750 mg) for self-administering twice a day from the start of menstrual pain for a duration of 3 days for 2 consecutive menstrual cycles. Subjects can take a maximum of 2 additional dose or 1 additional day for pain relief, in case pain persists after 3 days of Dysmegesic administration. Any rescue medication (analgesic) would be permitted after 2 hours of administration, if the test formulation would not be effective to control the symptoms. The details of extra dosing of Dysmegesic or rescue medication, will be noted in the subject dairy. A detailed clinical evaluation of dysmenorrhoea will be done. The efficacy of the test formulation will be assessed by VMS, NRS and MSQ questionnaire at the end of each cycle. The severity of dysmenorrhoea will be assessed by a Verbal Multidimensional Scoring system (VMS) and by Numeric Rating Score system for pain (NRS). Menstrual Symptom Questionnaire (MSQ) will be administered to evaluate the symptoms of dysmenorrhea. The tolerability of the test formulation will be assessed by incidence of adverse events reported.